Jim Simons
MRKR icon

Jim Simons’s Marker Therapeutics MRKR Stock Holding History

Jim Simons’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$367K Buy
249,423
+74,129
+42% +$108K ﹤0.01% 2714
2026
Q1 		$228K Buy
175,294
+51,644
+42% +$81.9K ﹤0.01% 2885
2025
Q4 		$184K Buy
123,650
+17,400
+16% +$19.7K ﹤0.01% 2903
2025
Q3 		$94.8K Buy
106,250
+36,808
+53% +$45.4K ﹤0.01% 3260
2025
Q2 		$106K Sell
69,442
-14,073
-17% -$18.1K ﹤0.01% 3290
2025
Q1 		$103K Buy
83,515
+43,465
+109% +$79.6K ﹤0.01% 3198
2024
Q4 		$125K Buy
40,050
+300
+0.8% +$1.06K ﹤0.01% 3253
2024
Q3 		$112K Buy
39,750
+900
+2% +$3.56K ﹤0.01% 3242
2024
Q2 		$211K Buy
38,850
+1,600
+4% +$6.8K ﹤0.01% 3029
2024
Q1 		$160K Sell
37,250
-300
-0.8% -$1.31K ﹤0.01% 3276
2023
Q4 		$207K Sell
37,550
-2,700
-7% -$9.15K ﹤0.01% 3122
2023
Q3 		$183K Buy
40,250
+8,300
+26% +$46.4K ﹤0.01% 3116
2023
Q2 		$99K Buy
31,950
+12,600
+65% +$21.9K ﹤0.01% 3476
2023
Q1 		$14K Buy
19,350
+3,030
+19% +$7.2K ﹤0.01% 3865
2022
Q4 		$43K Buy
16,320
+1,170
+8% +$4.04K ﹤0.01% 3825
2022
Q3 		$56K Sell
15,150
-11,620
-43% -$42.7K ﹤0.01% 3727
2022
Q2 		$88K Sell
26,770
-31,657
-54% -$105K ﹤0.01% 3879
2022
Q1 		$257K Sell
58,427
-48,473
-45% -$277K ﹤0.01% 3538
2021
Q4 		$1.02M Buy
106,900
+8,390
+9% +$111K ﹤0.01% 2624
2021
Q3 		$1.67M Buy
98,510
+58,520
+146% +$1.2M ﹤0.01% 2230
2021
Q2 		$1.12M Buy
+39,990
New +$1.05M ﹤0.01% 2617
2021
Q1 		– Sell
-31,836
Closed -$462K – 3566
2020
Q4 		$462K Buy
31,836
+9,136
+40% +$142K ﹤0.01% 2855
2020
Q3 		$341K Sell
22,700
-9,262
-29% -$169K ﹤0.01% 2952
2020
Q2 		$662K Buy
31,962
+8,492
+36% +$186K ﹤0.01% 2762
2020
Q1 		$446K Buy
23,470
+11,560
+97% +$295K ﹤0.01% 2814
2019
Q4 		$343K Buy
+11,910
New +$433K ﹤0.01% 3037

Other funds holding MRKR

BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Jim Simons's MRKR Position: Q2 2026 in Review

Jim Simons increased its Marker Therapeutics (MRKR) stake by 42% in Q2 2026, buying an estimated $108K and bringing the position to 249,423 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #2714.

Jim Simons first reported a position in MRKR in Q4 2019 and has held it in 26 quarters since. The position peaked at $1.67M in Q3 2021. 25 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

  • Jim Simons held 249,423 shares of Marker Therapeutics worth $367K as of Q2 2026.
  • Jim Simons bought 74,129 Marker Therapeutics shares in Q2 2026, an estimated $108K.
  • Marker Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #2714 holding.
  • Jim Simons first reported a position in Marker Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • Jim Simons's Marker Therapeutics position peaked at $1.67M in Q3 2021.
  • 25 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.